Doxazosin Tablet
Product Images NDC 71610-628

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 71610-628). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 8 mg (71610 0628 60)

Label for Doxazosin 8 mg tablets, containing 90 tablets per bottle. The label includes the NDC number 71610-0628-60 and storage instructions to keep between 20-25 degrees Celsius. The medication is manufactured by Greenstone LLC in Peapack, NJ, and repackaged by Aphena Pharma in Cookeville, TN. The label also features directions for storage, a barcode, batch and lot numbers, and indicates the product is RX Only.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Doxazosin 01

Chemical structure diagram of doxazosin mesylate, the active ingredient in Doxazosin 8 mg oral tablets by Aphena Pharma Solutions - Tennessee, LLC. The diagram depicts the molecular structure with labeled functional groups and bonding arrangements.*

FDA Label Image

Doxazosin 02

A summary chart displaying effectiveness data from placebo-controlled trials of doxazosin (Cardura®). It presents symptom score mean baseline and mean change, and maximum flow rate mean baseline and mean change for placebo and doxazosin doses (4 mg and 8 mg) across three studies. A bar graph on the right illustrates maximum flow rate and symptom score changes in Study 2 for placebo, 4 mg, and 8 mg doses.*

FDA Label Image

Doxazosin 03

This image contains two line graphs comparing the effects of Cardura and placebo over 14 weeks. The left graph shows the mean change in total symptom score from baseline, with Cardura showing a greater decrease than placebo. The right graph shows the mean increase in maximum urinary flow rate (mL/sec) from baseline, with Cardura showing a larger increase compared to placebo. The x-axes represent duration of treatment in weeks, and both graphs include sample sizes and statistical significance markers.*

FDA Label Image

Doxazosin 04

FDA Label Image

Doxazosin 04a

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.